UROV - Urovant Sciences inks co-promotion pact with Sunovion Pharma for Vibegron

Urovant Sciences (UROV) has entered into a five-year U.S. co-promotion agreement with Sunovion Pharmaceuticals Inc. to promote vibegron in the primary care segment, after receiving FDA approval for the drug. In March, the FDA accepted vibegron application for overactive bladder, with action date of December 26.Under the terms of the agreement, Sunovion will provide sales and marketing activities through March 31, 2026, and in return will will receive a mid-single digit repayment fee based on the net sales of vibegron beginning on April 1, 2023.The co-promotion agreement is in addition to the exclusive three-year agreement between Urovant and Sunovion for wholesale trade and retail distribution, contract operations, and select account management activities for vibegron.Sunovion Pharmaceuticals is a subsidiary of Sumitomo Dainippon Pharma, which is the majority shareholder of Urovant.

For further details see:

Urovant Sciences inks co-promotion pact with Sunovion Pharma for Vibegron